NorthWest Biotherapeutics Inc (NWBO)

[Doktornolittle]

Some here have stated that they are hopeful that CI adverse events will be lower when used in conjunction with DCVax-L because the CI dose required will be lower. I am one of those hopeful people.

But has anyone every seen a study suggesting this or a researcher speculating such? Even if not, I will still be hopeful.

But CI's and brain cancer is a delicate mix. The adverse events for CI are run-away inflammation... I believe. And such in the confines of a skull is not only dangerous but very scary if it can happen faster than it can be treated. So that is the seriousness of the issue. And for a child to have to experience such is very sad. But then so is GBM in general. So...

Hopefully DCVax-L as a combo to CI's will net reduce this hazard.
Further, the planned combo trial is with a different CI than this AE.
------------------------------------------------------------------

Adverse event child GBM --> Pembrolizumab --> Keytudra --> Merck
DCVax-L + CI for GBM --> Nivolumab --> Opdivo --> Bristol Meyers Squibb